NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

GRAIL, Inc. (GRAL) Stock Analysis

GRAIL, Inc. (GRAL) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

GRAL

$80.34

−$0.28 (−0.35%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GRAL with… →

GRAL Key Statistics

As of Sep 4, 2026
Trading
Open
$79.92
Previous Close
$80.62
Day's Range
78.50–80.51
52-Week Range
35.39–118.84
Volume
434.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.25
Valuation
Market Cap
$3.59B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
21.71
EPS (ttm)Profit attributable to each share over the last twelve months.
−9.69
Financials (FY)
Revenue (FY)
$147.17M+17.18%
Net Income (FY)
−$408.35M
Profit marginThe share of revenue left as profit after all costs and taxes.
−236.95%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
44.67M
1-Year Return
+139.18%
Dividend and dates
Earnings Date
November 11, 2026
Avg Volume
630.38K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GRAL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−6.13%
2025+379.50%
2024 (partial year)+30.67%

As of September 4, 2026.

GRAL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$147.17M−$408.35M−277.5%
2024$125.60M−$2.03B−1613.9%
2023$93.11M−$1.47B−1574.2%
2022$55.55M−$5.40B−9719.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$147.17M−$62.57M−$534.16M−$408.35M−277.5%
2024$125.60M−$78.02M−$768.22M−$2.03B−1613.9%
2023$93.11M−$95.61M−$796.92M−$1.47B−1574.2%
2022$55.55M−$116.45M−$742.46M−$5.40B−9719.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GRAL Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricGRALDiagnostics & Research medianvs median
P/S ratio21.714.994.4x the median
Profit margin−236.95%0.00%236.9 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values GRAIL, Inc. (GRAL) at $3.59B. It is classified in the Diagnostics & Research industry, within the Healthcare sector. The company reports 910 employees.

The most recent close on file for GRAL is $80.34, dated September 4, 2026. That is −$0.28 (−0.35%) against the previous close. The 52-week range on file runs from $35.39 to $118.84. The latest close sits 127.01% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $147.17M. That is +17.18% against the prior fiscal year, when revenue was $125.60M. The same year closed with a net loss of $408.35M. Profit margin runs at −236.95%. That is 236.9 percentage points below the Diagnostics & Research median of 0%. Earnings per share on a trailing basis come to −9.69.

Across the 4 fiscal years on file, revenue moves from $55.55M in 2022 to $147.17M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 21.71. On price-to-sales that is 4.4 times the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

The reported beta is 3.25. Annualized volatility over the trailing 2 years is 104.11%. The trailing one-year price return is +139.18%. The stored price history starts on June 12, 2024, and the total return since then is +488.14%.

Growth & Income

The record shows no dividend for GRAL.

2026 is still running; the price is −6.13% year to date. The record holds one complete calendar year, 2025, which returned +379.50%.

Peer Comparison

GRAIL, Inc. (GRAL) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
GRAIL, Inc. GRAL $3.59B —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. GRAIL, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About GRAIL, Inc.

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Visit website →